High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad

Journal of Public Health in Africa

Field Value
Title High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad
Creator Wondeu, Andrillene Laure Deutou Abdelrazakh, Fatima Abakar, Mahamat Fayiz Yandai, Fissou Henry Nodjikouambaye, Aleyo Zita Djimtoibaye, Djallaye Kimala, Pidou Nadjiadjim, Noel Naïbeï, Nathan Dzomo, Guy Rodrigue Takoudjou Atturo, Sabrina Linardos, Giulia Russo, Cristina Russo Perno, Carlo Federico Moussa, Ali Mahamat Yokouide, Allarangar Tchidjou, Hyppolite Kuekou Colizzi, Vittorio Choua, Ouchemi
Subject — COVID-19; Seroprevalence; SARS-CoV-2; Anti nucleocapsid antibodies; N’Djamena
Description Background. Since the start of the COVID-19 pandemic, Chad has had 7,417 confirmed cases and 193 deaths, one of the lowest in Africa.Objective. This study assessed SARS-CoV-2 immunity in N’Djamena.Methods. In August-October 2021, eleven N’Djamena hospitals collected outpatient data and samples. IgG antibodies against SARSCoV- 2 nucleocapsid protein were identified using ELISA. “Bambino Gesù” Laboratory, Rome, Italy, performed external quality control with chemiluminescence assay. Results. 25-34-year-old (35.2%) made up the largest age group at 31.9 12.6 years. 56.4% were women, 1.3 women/men. The 7th district had 22.5% and the 1st 22.3%. Housewives and students dominated. Overall seroprevalence was 69.5% (95% CI: 67.7-71.3), females 68.2% (65.8-70.5) and males 71.2% (68.6-73.8). 44-year-old had 73.9% seroprevalence. Under-15s were 57.4% positive. Housewives (70.9%), civil servants (71.5%), and health workers (9.7%) had the highest antibody positivity. N’Djamena’s 9th district had 73.1% optimism and the 3rd district had 52.5%. Seroprevalences were highest at Good Samaritan Hospital (75.4%) and National General Referral Hospital (74.7%).Conclusion. Our findings indicate a high circulation of SARSCoV- 2 in N’Djamena, despite low mortality and morbidity after the first two COVID-19 pandemic waves. This high seroprevalence must be considered in Chad’s vaccine policy.
Publisher AOSIS
Date 2022-12-31
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/xml application/pdf
Identifier 10.4081/jphia.2022.2255
Source Journal of Public Health in Africa; Vol 13, No 4 (2022); 12 2038-9930 2038-9922
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://publichealthinafrica.org/index.php/jphia/article/view/405/428 https://publichealthinafrica.org/index.php/jphia/article/view/405/444
Coverage — — —
Rights Copyright (c) 2024 Andrillene Laure Deutou Wondeu, Fatima Abdelrazakh, Mahamat Fayiz Abakar, Fissou Henry Yandai, Aleyo Zita Nodjikouambaye, Djallaye Djimtoibaye, Pidou Kimala, Noel Nadjiadjim, Nathan Naïbeï, Guy Rodrigue Takoudjou Dzomo, Sabrina Atturo, Giulia Linardos, Cristina Russo Russo, Carlo Federico Perno, Ali Mahamat Moussa, Allarangar Yokouide, Hyppolite Kuekou Tchidjou, Vittorio Colizzi, Ouchemi Choua https://creativecommons.org/licenses/by/4.0